anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pre-treatment characteristics of women with early breast cancer that are associated with persistent fatigue or suboptimal health-related quality of life (HRQOL) post-chemotherapy need to be identified as potential targets for pre-habilitation.
PATIENTS AND METHODS: Ancillary analysis of previously collected data from patients with newly diagnosed Stage I-III breast cancer scheduled to receive chemotherapy. The objective was to identify baseline (pre-chemotherapy) variables associated with meaningful deteriorations in fatigue and other measures of HRQOL from pre-treatment to 6 months after chemotherapy completion. Percentages are reported along with unadjusted and adjusted relative risks.
RESULTS: In a sample of 249 women post-chemotherapy, 32% reported worsening fatigue (FACIT-F), 35% worsening Physical Well-Being (PWB), 16% worsening Functional Well-Being (FWB), 8% worsening Emotional Well-Being (EWB), and 30% worsening Social Well-Being (SWB). In multivariable (MV) analysis, variables that were significant in univariate analysis - Black race, high BMI, and baseline poorer EWB - remained significant for worsening post-chemotherapy fatigue (FACIT-F). In MV analysis that included race, education, falls, and baseline EWB, Black race and a positive falls history remained significant for worsening PWB. In MV analysis inclusive of race, Short Physical Performance Battery (SPPB) and FWB, lower SPPB and FWB remained significant predictors of worsening FWB. In MV analysis that included baseline Mental Health Index-Anxiety, EWB and SWB, a higher SWB and lower EWB remained significant for worsening SWB.
CONCLUSION: Pre-chemotherapy characteristics in women with early-stage breast cancer that are associated with increased fatigue and reduced HRQOL post-treatment could be used to identify patients who may benefit from pre-habilitation interventions.
A self-adjuvanting immunogenic composition comprising an immunogen comprising a lipopeptide cap (R2), a universal T helper sequence (R1) and an immunodominant Aβ B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The B cell epitope of each immunogen has an amino acid sequence located within the first 17 amino acids of SEQ ID NO: 1. The lipopeptide is a dipalmitoyl-S-glyceryl-cysteine or a tripalmitoyl-S-glyceryl cysteine or N-acetyl (dipalmitoyl-S-glyceryl cysteine), each with an optional neutral amino acid linker. Optional polar sequences of at least four charged polar amino acids enhance solubility of the immunogen and are located at the carboxy terminal end of R2, optionally flanked by neutral linker amino acids, or elsewhere in the immunogen. Such compositions, at surprisingly low dosages of less than 10 mg per subject, can induce anti-A/8 peptide antibodies with GMTs of 50,000 or greater than 1,000,000 when employed to immunize a mammalian subject, without any extrinsic adjuvant.
Renal cell carcinoma (RCC) the most common type of kidney cancer in adults is responsible for about 3% of all cancers and is twice as often in men as in women. Sex hormones (estrogen especially) play a protective role in cancer inhibition and synergistic effect with anticancer drug. Even so, no hormonal regimen is accepted as a definite management for RCC until today. This invention firstly treated RCC cells that present estrogen-receptor (ER) 1 expression with estrogen (17 β -estradiol) in combine with chemotherapeutic agent (paclitaxel). Then, We analyzed the cancer cells with cell proliferation rates, apoptosis, and intracellular reactive oxygen species with Cell Counting Kit-8, 2', 7'-dichlorfluorescein-diacetate, respectively. Our results show that the cancer cells underwent apoptosis which brought out the significant dropping of relative growth rate and caused from oxidative stress. This contrivance is the first time to treated RCC cells with sex hormone in coupled with a chemotherapeutic agent. Moreover, we expect that a gender-specific therapeutic strategy would be constructed and improve the prognoses of RCC.
OBJECTIVES: Cerebral venous thrombosis is an uncommon, yet life-threatening condition, affecting mainly young and middle-aged individuals. Moreover, it represents an underrecognised etiology of lobar intracerebral hemorrhage (ICH). The clinical course of CVT is variable in the first days after diagnosis and medical complications including pulmonary embolism (PE) may result in early neurological deterioration and death if left untreated.
MATERIALS AND METHODS: Case report.
RESULTS: We describe a 46-year-old man with acute left hemiparesis and dysarthria in the context of lobar ICH due to underlying CVT of Trolard vein. Diagnosis was delayed because of misinterpretation of the initial neuroimaging study. Subsequently, the patient rapidly deteriorated and developed submassive PE and left iliofemoral venous thrombosis in the setting of previously undiagnosed hereditary thrombophilia (heterozygous prothrombin gene mutation G2021A). Emergent aspiration thrombectomy was performed resulting in the successful management of PE. A follow-up MRI study confirmed the thrombosed Trolard vein, thus establishing the CVT diagnosis. Anticoagulation treatment was immediately escalated to enoxaparine therapeutic dose resulting in clinical improvement of neurological deficits.
CONCLUSIONS: Delayed diagnosis of cerebral venous thrombosis with underlying causes of lobar ICH may result in dire complications. Swift initiation of anticoagulants is paramount even in patients with lobar intracerebral hemorrhage as the initial manifestation of cerebral venous thrombosis.
The Human Microbiome Project (HMP), started in 2008, aimed to characterize the microbial communities on the skin, in the oral and nasal cavities, and in the gastrointestinal and urogenital tracts. This project cross-sectionally described the microbial communities in a healthy human population, but did not adequately describe longitudinal stability. Out of the 236 adults included in the HMP, a second saliva sample was collected on a small subset (N=74) with a long interval between collections, an average of 203 days. Community similarity was calculated between two visits; for saliva samples, the Spearman correlation was high (rs=0.8). However, it was unclear which metric of community similarly was being used for this calculation. When we obtained the HMP data and calculated the Spearman correlation for specific diversity metrics in the saliva samples, the correlations were weaker and ranged from 0.225 to 0.524 for the Shannon Index and PD tree, respectively. Other studies with fewer people, but more time points, have had conflicting conclusions on the temporal variation of the oral microbiome. Given this variability, it is vital to establish whether a single measurement is representative of the typical composition of microbiota in a specific body site using more than two time points.

In epidemiological studies, it is often impractical, if not impossible, to collect biological samples or measurements multiple times for each participant during the study period. However, when a biological sample or a measurement is taken only once, there is concern that the single assessment is not representative of the typical value. For example, serum 25(OH)D levels, which are used to assess an individual s vitamin D exposure, have seasonal fluctuations, but studies have established that a single measurement is sufficiently reliable to represent typical exposure. The correlation between samples over time is also used to create more accurate power calculations for future studies.

Since previous work has not adequately addressed temporal variation in the oral microbiome, we propose to: 1) establish a cohort of 40 adults willing to provide oral samples approximately every two months for one year; 2) process all oral samples and evaluate the presence and quantity of microbiota using 16S ribosomal RNA gene sequencing; 3) calculate appropriate reliability measures for the sample over time using the intra-class correlation coefficient (ICC) for and \<= diversity metrics; and 4) empirically evaluate the efficiency of different longitudinal designs including two or more sample collections with an outcome such as body mass index (BMI). Because of the complexity and high prevalence of human DNA in saliva, metagenomic analyses of oral samples are not yet feasible, however, the samples obtained from this study will be available for use in future metagenomic analyses when the technology is operationalized. The current study is essential to establish the reliability of a single measure of the oral microbiome to determine appropriate sample sizes for future cohort studies considering the effect of the oral microbiome on the risk of cancer and other health outcomes.
Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
Inhalation of particulate matter (PM), one of the many components of air pollution, is associated with the development and exacerbation of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD). COPD is one of the leading causes of global mortality and morbidity, with a paucity of therapeutic options and a significant contributor to global health expenditure. This review aims to provide a mechanistic understanding of the cellular and molecular pathways that lead to the development of COPD following chronic PM exposure. Our review describes how the inhalation of PM can lead to lung parenchymal destruction and cellular senescence due to chronic pulmonary inflammation and oxidative stress. Following inhalation of PM, significant increases in a range of pro-inflammatory cytokines, mediated by the nuclear factor kappa B pathway are reported. This review also highlights how the inhalation of PM can lead to deleterious chronic oxidative stress persisting in the lung post-exposure. Furthermore, our work summarises how PM inhalation can lead to airway remodelling, with increases in pro-fibrotic cytokines and collagen deposition, typical of COPD. This paper also accentuates the interconnection and possible synergism between the pathophysiological mechanisms leading to COPD. Our work emphasises the serious health consequences of PM exposure on respiratory health. Elucidation of the cellular and molecular mechanisms can provide insight into possible therapeutic options. Finally, this review should serve as a stark reminder of the need for genuine action on air pollution to decrease the associated health burden on our growing global population.
-a-ABSTRACT OF THE DISCLOSURE The  present specification discloses a class of chemical compounds the members of which when introduced by ingestion, injection, absorption, or otherwise into a mammal (including man), produce avoidance, amelioration and/or inprovement of a hyper-tensive conditon in mammals and man when used in an antihyper-tensively effective amount as taught herein.  The active anti-hypertensive agents used in the compositions of the present invention fall into four broad categories. They are:      (1) the inorganic salts of sulfurous acid which display anti-hypertensive activity, specifically the alkali metal, alkaline earth metal, and ammonium salts of sulfites and bisulfites (including metabisulfites) and mixtures thereof.  Alkali metal, particularly sodium and potassium bisulfites are preferred active agents, and, of these, sodium bisulfite is a presently most pre-ferred active agent.  Also, because of similar toxicological considerations, the calcium, magnesium, and ammonium compounds are also preferred.      (2)  A compound of the formula:                         in which R is hydrogen or hydroxymethyl, R1 is hydrogen, a straight chain alkyl containing 2 to 5 hydroxylated carbon atoms, or residue of a polysaccharide capable of reducing Fehling's solution, while X is an alkali metal or ammonium.  Illustrative compounds include sodium glucose bisulfite and sodium formaldehyde bisulfite.      (3)  A lower alkyl amine sulfite compound of the formula:     - b -  where R1 is lower alkyl, cycloalkly containing from 6 to 10 carbon atoms each, lower monohydroxyalkyl or aralkyl, R2 is hydrogen, lower alkyl or lower monohydroxyalkyl, or R1 and R2 together constitute a morpholine, piperidine, or hexamethyleneimine ring, provided that each such ring can be substituted on one of its carbon atoms by lower alkyl radical, R3 is lower aalkyl, lower monohydroxyalkyl, hydrogen, or a compound of the formula:               in which R4 is a divalent saturated lower aliphatic radical, m and n are intergers, the sum of m and n is 2, and n is eithr 0 or 1.
PURPOSE:To provide a carcinostatic agent containing a specific platinum complex as an active component. CONSTITUTION:The objective carcinostatic agent contains cis-dichloro-trans- dihydroxo(2-aminomethylpyrrolidine)platinum (IV) of formula as an active component. The agent is administered in the form of an oral drug such as a solid preparation (e.g. tablet, pill, capsule, etc.) or liquid preparation (e.g. solution, suspension, etc.) or a parenteral drug such as injection, suppository, etc., at a dose of 200-400mg/kg daily for oral drug and 100-200mg/kg daily for parenteral drug. The compound of formula used as an active component can be produced by reacting platinum (II) potassium chloride with 2- aminomethylpyrrolidine and reacting the resultant dichloro-2- aminomethylpyrrolidine)platinum (II) with hydrogen peroxide. EFFECT:It has excellent anti-tumor activity and definitely weak bonding power to plasma protein compared with conventional platinum complex and CDDP, etc., and is useful as a carcinostatic agent.
The invention belongs to the technical field of biological medicines, and particularly discloses application of short-chain fatty acid in vascular related diseases. Use of short chain fatty acids in the preparation of inhibitors of MMP2 and/or MMP9 expression. Application of short-chain fatty acid in preparation of preparation for inhibiting degradation of vascular elastic fiber. The application of short-chain fatty acid in preparing medicine for preventing and treating vasodilation is disclosed. The application of short-chain fatty acid in preparing medicine for preventing and treating aneurysm diseases is disclosed. The application of the short-chain fatty acid-Treg combined agent in preparing the medicine for preventing and treating the aneurysm diseases. The short-chain fatty acid-Treg combined preparation is applied to the preparation of the medicament for inhibiting the degradation of the elastic fibers of the aneurysm. Use of short chain fatty acids in the manufacture of a medicament for promoting the recirculation of colonic lamina propria Tregs to an aneurysm. The invention expands the new application of the short-chain fatty acid. Provides a novel MMP2 and/or MMP9 expression inhibitor, and simultaneously provides a medicament for treating vascular diseases, particularly has better treatment effect on vasodilatation, aneurysm and the like.
Background. Body pain of various degrees and types can complicate human life. Regular physical exercise and good mental health can both have protective effects on the body and its physical health. Physical exercises may also, in some aspects, be particularly important for older women who experience varying degrees of headache, back pain, and/or leg pain chronically. The purpose of the study was to analyze the effects of the Dalcroze Eurhythmic Method on headaches, backaches, and leg pains among older women.

Methods. Sixty-two blinded participants with pain were randomized into two groups. Women (65 to 82 years old) who had reported the occurrence of headaches, backaches, or leg pains during the 3 months prior to the beginning of the randomized controlled trial study were identified. The participants in the pre-test and post-test used the 0-10 Numeric Pain Rating Scale to quantify their pain. Women from the experimental group participated for 3 months in the physical exercise program based on the Dalcroze Eurhythmics Method.
Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
Most patients with advanced melanomas have a known primary site [melanoma of known primary (MKP)]. However, 2%-9% of patients are diagnosed with melanoma metastasis of unknown primary (MUP). As MUP and MKP have similar UV-induced mutations and molecular signatures, it is proposed that the primary tumor has regressed completely in patients with MUP. As regression of the primary tumor could be indicative of enhanced recognition of melanoma antigens, we hypothesize that patients with advanced MUP have a better outcome compared with MKP.Patients with advanced MUP from 10 German university hospitals were retrospectively analyzed and matched with MKP based on the type of systemic treatment (BRAF and MEK inhibitors, PD-1 inhibitor monotherapy, combined CTLA-4 and PD-1 inhibitor therapy) therapy line (first or second line) and AJCC stage (IIIC, IV M1a-M1d). Three hundred thirty-seven patients with MUP were identified, and 152 treatments with PD-1 and CTLA-4 inhibitors, 142 treatments with PD-1 inhibitors, and 101 treatments with BRAF and MEK inhibitors were evaluated. Median time to treatment failure was significantly prolonged in patients with MUP treated with PD-1 monotherapy (17 mo, 95% CI: 9-25, P = 0.002) compared with MKP (5 mo, 95% CI: 3.4-6.6), as well as in MUP treated with combined PD-1 and CTLA-4 therapy (11 mo, 95% CI: 4.5-17.5, P < 0.0001) compared with MKP (4 mo, 95% CI: 2.9-5.1) Occurrence of immune-related adverse events and time to treatment failure for patients with BRAF and MEK inhibitors was similar in MKP and MUP. In our multicentre collective, patients with MUP have better outcomes under immunotherapy compared with MKP.
Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
The present invention relates to a food composition for relieving hangover, containing Lactococcus lactis subsp. cremoris or a culture liquid thereof as an active ingredient. Specifically, functional cream cheese is manufactured by using Lactococcus lactis subsp. cremoris having an ability to degrade ethanol and acetaldehyde. The functional cream cheese is preferably used as functional health food for relieving hangover, and in a broad sense, can minimize the accumulation of acetaldehyde capable of causing cancer in vivo, by degrading acetaldehyde which is an ethanol degraded product. In addition, the functional cream cheese is a cheese starter for lowering the unit cost compared with commercial cream cheese, and can be differentiated from cream cheese on the market.
Placebo arm patients will receive volume-matching placebo 1 mL, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
The invention belongs to a compound veterinary medicine preparation for treating avian enteritis type colibacillosis in veterinary medicine. The preparation consists of three main medicinal components and an adjuvant; three main medicinal components include 3.25%W/W of neomycin sulfate, 0.81%W/W of lactic acid TMP (Trimethoprim) and 10%W/W of glutamine; and the adjuvant includes 85.94%W/W of glucose. The veterinary medicine preparation is utilized to treat the avian enteritis type colibacillosis. A processing technology of the composition is as follows: respectively grinding, screening and accurately weighing the components according to the necessary ratio, mixing for 25 min, and performing semi-finished product quality control, split charging, packaging and finished product quality control to obtain the composition. An application method is as follows: drinking the water in 1% level of the composition, and a course of treatment lasts for 4 days. The compound veterinary medicine preparation provided by the invention is remarkable in efficacy of avian enteritis type colibacillosis, low in drug resistance, safe and low toxicity, thereby having good popularization and application value.
A compound of the formula <IMAGE> or a pharmaceutically acceptable salt thereof, wherein: G is hydroxymethylene or carbonyl; R is hydrogen or alkanoyl having from one to seven carbon atoms; R1 and R2 are each methyl or ethyl; R3 is an alkyl of from five to seven carbon atoms; m is 0 or 1; and n is 1, 2 or 3. A preferred compound is one in which m is zero, n is one or G is hydroxymethylene. Also preferred are compounds in which R1 and R2 are methyl. Additional preferred compounds include those where R is hydrogen or acetyl. A preferred compound is Z-3-(4'-(dimethyl-n-hexylsilyl)-2'-hydroxyphenyl)cyclohexanol. The invention further comprises pharmaceutical compositions containing these compounds. In accordance with the present invention, these compounds when administered in an effective amount to mammals are useful as CNS agents including analgesics, tranquilizers, sedatives, anticonvulsants, antidiarrheals, antiemetics and antianxiety agents.
[US4379783A]